Successful execution of drug development and discovery strategies is necessary but not always sufficient to transform a novel idea into a commercially viable drug. Many early stage drug candidates fail during preclinical or clinical development due to the lack of an effective plan for preclinical and clinical evaluations of the individual drug candidates. Each step of QPS's drug development process, from preclinical testing and analysis through the completed collection of the data gathered is designed with careful efficiency.

According to recent pharmaceutical industry data, it takes an average of 10-15 years and over $800 million dollars to discover, develop, and receive FDA regulatory approval for a new chemical entity (NCE). Any delays in regulatory approval of a novel treatment for an unmet medical need translate into delayed therapeutic benefits for patients and decreased financial benefits for drug companies. At QPS, we monitor each step of the drug develpment process, from pre-testing to the bottom line for our clients and partners.

To minimize the failure rate of NCEs and shorten the duration from discovery to development, a strategy must be in place at the time a compound is ready for development. At QPS Pharmaceutical Services , our drug development plan is the basis for the strategy and execution of studies required to support submission of an Investigational New Drug (IND) application.